Maridebart Cafraglutide
Sponsors
Amgen
Conditions
Atherosclerotic Cardiovascular DiseaseHeart Failure With Mildly Reduced Ejection FractionHeart Failure With Preserved Ejection FractionObesityObesity DiseaseObstructive Sleep ApneaOverweightOverweight and Obesity
Phase 1
Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity
CompletedNCT04478708
Start: 2020-08-07End: 2022-11-18Updated: 2025-12-10
A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight
CompletedNCT06352892
Start: 2024-04-25End: 2024-08-27Updated: 2026-01-08
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
RecruitingNCT07160257
Start: 2025-08-05End: 2026-12-13Target: 70Updated: 2025-12-01
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations
Active, not recruitingNCT07226778
Start: 2025-10-10End: 2026-05-28Updated: 2026-02-10
Effect of Maridebart Cafraglutide on the Heart's Electrical Activity
Active, not recruitingNCT07229157
Start: 2025-10-22End: 2026-08-26Updated: 2026-01-23
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
Active, not recruitingNCT07313761
Start: 2025-12-15End: 2026-06-26Updated: 2026-03-19
Phase 2
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
CompletedNCT05669599
Start: 2023-01-18End: 2025-12-16Updated: 2026-01-20
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
Active, not recruitingNCT06660173
Start: 2024-11-07End: 2026-11-10Updated: 2025-11-25
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
RecruitingNCT07441252
Start: 2026-03-05End: 2027-12-22Target: 180Updated: 2026-04-02
Phase 3
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Active, not recruitingNCT06858839
Start: 2025-03-12End: 2027-04-16Updated: 2025-10-17
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Active, not recruitingNCT06858878
Start: 2025-03-17End: 2027-04-16Updated: 2025-12-31
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
Active, not recruitingNCT06987695
Start: 2025-06-13End: 2027-07-21Updated: 2025-12-17
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
RecruitingNCT07037459
Start: 2025-06-25End: 2030-09-29Target: 5056Updated: 2026-04-02
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
RecruitingNCT07037433
Start: 2025-07-25End: 2030-09-29Target: 12800Updated: 2026-03-27
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
RecruitingNCT07225686
Start: 2025-12-19End: 2028-09-13Target: 250Updated: 2026-04-02
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
RecruitingNCT07226765
Start: 2025-11-25End: 2028-09-13Target: 250Updated: 2026-04-02